H Jiang1, D L Robinson2, P V S Lee2, E O Krejany3, C J Yates1,4,5, M Hickey3, J D Wark6,7,8. 1. Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, 3050, Australia. 2. Department of Biomedical Engineering, University of Melbourne, Parkville, Australia. 3. Department of Obstetrics and Gynaecology, University of Melbourne and Royal Women's Hospital, Parkville, Australia. 4. Bone and Mineral Medicine, Royal Melbourne Hospital, Parkville, Australia. 5. Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Australia. 6. Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, 3050, Australia. jdwark@unimelb.edu.au. 7. Bone and Mineral Medicine, Royal Melbourne Hospital, Parkville, Australia. jdwark@unimelb.edu.au. 8. Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Australia. jdwark@unimelb.edu.au.
Abstract
Prophylactic oophorectomy is recommended for women at high risk for ovarian cancer, but the associated impact on bone health is of clinical concern. This prospective, controlled study demonstrated substantial loss of bone density and bone strength following surgical menopause. Postoperative hormone therapy alleviated, but not fully prevented, spinal bone loss. INTRODUCTION: This prospective study investigated bone health in women following premenopausal oophorectomy. METHODS: Dual-energy x-ray absorptiometry (DXA), peripheral quantitative computed tomography (pQCT), and pQCT-based finite element analysis (pQCT-FEA) were used to assess bone health between systemic hormone therapy (HT) users and non-users after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared with premenopausal controls over 24-month follow-up. RESULTS: Mean age was 42.4 ± 2.6 years (n = 30) for the surgery group and 40.2 ± 6.3 years for controls (n = 42), and baseline bone measures were similar between groups. Compromised bone variables were observed at 24 months after RRBSO, among which areal bone mineral density (aBMD) at the lumbar spine, tibial volumetric cortical density (Crt vBMD), and tibial bending stiffness (kbend) had decreased by 4.7%, 1.0%, and 12.1%, respectively (all p < 0.01). In non-HT users, significant losses in lumbar spine (5.8%), total hip (5.2%), femoral neck (6.0%) aBMD, tibial Crt vBMD (2.3%), and kbend (14.8%) were observed at 24 months (all p < 0.01). HT prevented losses in kbend, tibial Crt vBMD, and aBMD, except for modest 2.3% loss at the lumbar spine (p = 0.01). CONCLUSION: This prospective, controlled study of bone health following RRBSO or premenopausal oophorectomy demonstrated substantial loss of bone density and bone strength following RRBSO. HT prevented loss of bone density and bone stiffness, although there was still a modest decrease in lumbar spine aBMD in HT users. These findings may inform decision-making about RRBSO and clinical management following premenopausal oophorectomy.
Prophylactic oophorectomy is recommended for women at high risk for ovarian cancer, but the associated impact on bone health is of clinical concern. This prospective, controlled study demonstrated substantial loss of bone density and bone strength following surgical menopause. Postoperative hormone therapy alleviated, but not fully prevented, spinal bone loss. INTRODUCTION: This prospective study investigated bone health in women following premenopausal oophorectomy. METHODS: Dual-energy x-ray absorptiometry (DXA), peripheral quantitative computed tomography (pQCT), and pQCT-based finite element analysis (pQCT-FEA) were used to assess bone health between systemic hormone therapy (HT) users and non-users after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared with premenopausal controls over 24-month follow-up. RESULTS: Mean age was 42.4 ± 2.6 years (n = 30) for the surgery group and 40.2 ± 6.3 years for controls (n = 42), and baseline bone measures were similar between groups. Compromised bone variables were observed at 24 months after RRBSO, among which areal bone mineral density (aBMD) at the lumbar spine, tibial volumetric cortical density (Crt vBMD), and tibial bending stiffness (kbend) had decreased by 4.7%, 1.0%, and 12.1%, respectively (all p < 0.01). In non-HT users, significant losses in lumbar spine (5.8%), total hip (5.2%), femoral neck (6.0%) aBMD, tibial Crt vBMD (2.3%), and kbend (14.8%) were observed at 24 months (all p < 0.01). HT prevented losses in kbend, tibial Crt vBMD, and aBMD, except for modest 2.3% loss at the lumbar spine (p = 0.01). CONCLUSION: This prospective, controlled study of bone health following RRBSO or premenopausal oophorectomy demonstrated substantial loss of bone density and bone strength following RRBSO. HT prevented loss of bone density and bone stiffness, although there was still a modest decrease in lumbar spine aBMD in HT users. These findings may inform decision-making about RRBSO and clinical management following premenopausal oophorectomy.
Entities:
Keywords:
DXA; Finite element analysis; Hormone replacement; Surgical menopause; pQCT
Authors: Ingrid E Fakkert; Elske Marije Abma; Iris G Westrik; Joop D Lefrandt; Bruce H R Wolffenbuttel; Jan C Oosterwijk; Riemer H J A Slart; Eveline van der Veer; Geertruida H de Bock; Marian J E Mourits Journal: Eur J Cancer Date: 2014-12-18 Impact factor: 9.162
Authors: J V Cohen; L Chiel; L Boghossian; M Jones; J E Stopfer; J Powers; T R Rebbeck; K L Nathanson; S M Domchek Journal: Fam Cancer Date: 2012-03 Impact factor: 2.375
Authors: Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: Jau-Yi Li; Benoit Chassaing; Abdul Malik Tyagi; Chiara Vaccaro; Tao Luo; Jonathan Adams; Trevor M Darby; M Neale Weitzmann; Jennifer G Mulle; Andrew T Gewirtz; Rheinallt M Jones; Roberto Pacifici Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808
Authors: J Challberg; L Ashcroft; F Lalloo; B Eckersley; R Clayton; P Hopwood; P Selby; A Howell; D G Evans Journal: Br J Cancer Date: 2011-06-07 Impact factor: 7.640
Authors: Joanne Kotsopoulos; Elizabeth Hall; Amy Finch; Hanxian Hu; Joan Murphy; Barry Rosen; Steven A Narod; Angela M Cheung Journal: JAMA Netw Open Date: 2019-08-02